Compare Cassava Sciences Inc (FLNA) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares MBS ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while iShares MBS ETF trades at $89.7 (market cap $35.45B). The key difference: iShares MBS ETF is far larger — about 899.7× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 4,982,386). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and iShares MBS ETF for 96 Days on average.
| FLNA | MBB | |
|---|---|---|
Market Cap | $39.40M | $35.45B |
Volume | 759,018 | 4,982,386 |
Sector | Health | Fixed Income |
52-Week High | $4.64 | $96.91 |
52-Week Low | $0.68 | $89.09 |
Typical Hold Time | 37 Days | 96 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
MBB, the iShares MBS ETF, trades at $89.22, down 0.16% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The ETF faces headwinds from rising intermediate-term rates and inflation, as noted in recent analysis, while short interest has surged significantly. Recent corporate actions include scheduled dividend payments, but key financial ratios are not available in the provided data.
The outlook for MBB is cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. Investment opportunities exist for income-focused investors attracted to its dividend yield, but risks include further rate hikes and prepayment volatility. Investors should weigh the ETF's role in a diversified fixed income portfolio against potential duration-related losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
